PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R. 4368: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 5894: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 H.R. 2670: National Defense Authorization Act for Fiscal Year 2024 S. 2226: National Defense Authorization Act for Fiscal Year 2024 S. 2131: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S. 2624: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 FY 2024 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (P.L. 117-180)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE ELIZABETH ESPOSITO | — |
| BART FORSYTH | — |
| PAUL GAGE | — |
| KELLY GOLDBERG | — |
| SAMANTHA HELTON ABBOUD | — |
| JAIMON M JACKSON | — |
| RYAN KAAT | — |
| DAVID KORN | — |
| NICHOLAS LISOWSKI | — |
| COLLEEN MALONEY | — |
| TOM O'BRIEN | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| ZACH SENTEMENTES | — |
| JOCELYN ULRICH | — |
| ANNIE WOERPEL | — |
| MICHAEL PAUL WOODY | — |
Copyright/Patent/Trademark CPT
H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023 H.R. 4370: PREVAIL Act - Provisions related to the PTAB H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues H.R. 5429: Medication Affordability and Patent Integrity Act H.R. 5475: Prohibiting Adversarial Patents Act of 2023 S. 79: Interagency Patent Coordination and Improvement Act of 2023 S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2220: PREVAIL Act - Provisions related to the PTAB S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents S. 2780: Medication Affordability and Patent Integrity Act Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent use codes policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELENORA CONNORS New | Legislative Assistant - Sen. Dianne Feinstein |
| BART FORSYTH | — |
| PAUL GAGE | — |
| KELLY GOLDBERG | — |
| RYAN KAAT | — |
| DAVID KORN | — |
| NICHOLAS LISOWSKI | — |
| JOHN NAPPI | — |
| ZACH SENTEMENTES | — |
| JOCELYN ULRICH | — |
Health Issues HCR
H.R. 167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3284: Providers and Payers COMPETE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4507: Transparency in Coverage Act of 2023 H.R. 4508: Hidden Fee Disclosure Act H.R. 4822: Health Care Price Transparency Act of 2023 H.R. 4882: Clinical Laboratory Price Transparency Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act H.R. 5378: Lower Costs, More Transparency Act H.R. 5539: ORPHAN Cures Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1128: Ensuring Access to Generic Medications Act S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2840: Bipartisan Primary Care and Health Workforce Act Inflation Reduction Act of 2022 (P.L. 117-169) Nomination of Dr. Monica Bertagnolli as NIH director Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Supply chain policy issues Mental health policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Cybersecurity policy issues Anticounterfeiting policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| SANDY AHN | — |
| ELENORA CONNORS New | Legislative Assistant - Sen. Dianne Feinstein |
| ANNE ELIZABETH ESPOSITO | — |
| BART FORSYTH | — |
| PAUL GAGE | — |
| KELLY GOLDBERG | — |
| JUDITH HARON | — |
| SAMANTHA HELTON ABBOUD | — |
| JAIMON M JACKSON | — |
| RYAN KAAT | — |
| DAVID KORN | — |
| NICHOLAS LISOWSKI | — |
| COLLEEN MALONEY | — |
| JOHN NAPPI | — |
| TOM O'BRIEN | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| CORBIN SANTO | — |
| ZACH SENTEMENTES | — |
| BRIDGETT TAYLOR | — |
| JOCELYN ULRICH | — |
| JULIE WAGNER | — |
| ANNIE WOERPEL | — |
| SCOTT WOODS | — |
| MICHAEL PAUL WOODY | — |
| SYLVIA YU | — |
Medicare/Medicaid MMM
H.R. 485: Protecting Health Care for All Patients Act of 2023 - To amend title XI of the Social Security Act to prohibit the use of quality-adjusted life years and similar measures in coverage and payment determinations under Federal health care programs H.R. 2666: Medicaid VBPs for Patients Act or MVP Act Inflation Reduction Act of 2022 (P.L. 117-169) Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Rebate policy issues Insulin policy issues Value-based purchasing arrangements policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) and model policy issues CMMI Cell and Gene Therapy Access Model Medicaid rebates and waiver policy issues CMS Guidance on the Medicare Drug Price Negotiation Program: Initial Memorandum [ ] IPAY 2026 and Solicitation of Comments CMS Medicare Drug Price Negotiation Revised Guidance CMS Guidance on Medicare Part B and D Inflation Rebates Medicaid Drug Rebate Program Proposed rule (CMS-2434-P)
| Lobbyist | Covered position, as disclosed |
|---|---|
| RANDY BURKHOLDER | — |
| ELENORA CONNORS New | Legislative Assistant - Sen. Dianne Feinstein |
| BART FORSYTH | — |
| PAUL GAGE | — |
| JUDITH HARON | — |
| SAMANTHA HELTON ABBOUD | — |
| NICHOLAS LISOWSKI | — |
| COLLEEN MALONEY | — |
| JOHN NAPPI | — |
| TOM O'BRIEN | — |
| LORI REILLY | — |
| CORBIN SANTO | — |
| JOCELYN ULRICH | — |
| SCOTT WOODS | — |
| SYLVIA YU | — |
Trade (domestic/foreign) TRD
H.R. 3858: No Free TRIPS Act S. 1834: No Free TRIPS Act H.R. 4307: Medical Supply Chain Resiliency Act S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELENORA CONNORS New | Legislative Assistant - Sen. Dianne Feinstein |
| BART FORSYTH | — |
| PAUL GAGE | — |
| DAVID KORN | — |
| NICHOLAS LISOWSKI | — |
| JOHN NAPPI | — |
| ZACH SENTEMENTES | — |
| JOCELYN ULRICH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.